Company: EDSA
Filing Date: 2025-12-12
Form Type: 10-K
Source: 0001171843-25-007914
Chunk: 1596

Company: Edesa Biotech, Inc.
Filing Date: 2025-12-12
Form: 10-K
Item: Item 13
Chunk 1596
---
,220
			)

			(171,937
			)

			(23,446
			)

			-

			-

			(748,588
			)

			Preferred return on Series A-1 preferred shares

			-

			-

			136,438

			-

			-

			-

			(136,438
			)

			-

			Share-based compensation

			-

			-

			-

			-

			729,642

			729,642

			Net loss and comprehensive loss

			76,842

			(7,185,523
			)

			(7,108,681
			)

			Balance - September 30, 2025

			7,141,783

			$
			54,515,421

			$
			1,092,133

			$
			8,168,063

			$
			14,753,110

			$
			(165,771
			)
			 
			$
			(65,910,974
			)
			 
			$
			12,451,982

The accompanying notes are an integral part of these consolidated financial statements.

F-7

EDESA BIOTECH, INC.

Notes to Consolidated Financial Statements

For the Years Ended September 30, 2025 and 2024

1. Nature of operations

Edesa Biotech, Inc. (the “Company” or “Edesa”) is a biopharmaceutical company focused on acquiring, developing and commercializing clinical stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. The Company is organized under the laws of British Columbia, Canada and is headquartered in Markham, Ontario. It operates under its wholly owned subsidiaries, Edesa Biotech Research, Inc., an Ontario, Canada corporation, and Edesa Biotech USA, Inc., a California, USA corporation.

The Company’s common shares trade on The Nasdaq Capital Market in the United States under the symbol “EDSA”.

Going Concern

These consolidated financial statements have been prepared on a going concern basis which presumes the realization of assets and the discharge of liabilities in the normal course of operations for at least the next twelve months.

For the year ended September 30, 2025, the Company incurred a comprehensive loss of $7.1 million